Apr 11, 2025
IMDELLTRA® DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER
Apr 03, 2025
UPLIZNA® (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE
Mar 13, 2025
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKS
Mar 08, 2025
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Mar 04, 2025
AMGEN ANNOUNCES 2025 SECOND QUARTER DIVIDEND
Feb 07, 2025
AMGEN TO PRESENT AT THE 35th ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
Jan 31, 2025
AMGEN ANNOUNCES WEBCAST OF 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Jan 08, 2025
AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Nov 29, 2024
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
Nov 26, 2024
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
Nov 13, 2024
AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
Nov 08, 2024
AMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
Nov 08, 2024
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Oct 01, 2024
LA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
Sep 24, 2024
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Sep 23, 2024
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
Sep 09, 2024
AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA(TM) (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
Aug 30, 2024
AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
Aug 20, 2024
OTEZLA® (APREMILAST) NOW AVAILABLE IN THE U.S. FOR MODERATE TO SEVERE PEDIATRIC PLAQUE PSORIASIS
Aug 06, 2024
AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS